Navigation Links
Surgery Viable for Advanced Prostate Cancer, Study Finds

TUESDAY, May 17 (HealthDay News) -- Surgery to remove the prostate gland (radical prostatectomy) led to a 20-year survival rate for 80 percent of patients with advanced prostate cancer, a new study finds.

The study included patients with cancer that had spread beyond the prostate, known as cT3 prostate cancer, and underwent radical prostatectomy between 1987 and 1997.

The 80 percent survival rate in these patients compares to a 90 percent survival rate at 20 years for patients with cancer confined to the prostate (cT2 prostate cancer), the Mayo Clinic researchers said.

Previously, patients with cT3 prostate cancer were offered radiation or hormone treatment, but not radical prostatectomy, the study authors noted in a Mayo news release.

"We are doing a much better job of identifying and expanding candidates for surgery, which results in better, longer outcomes for so many of our patients," Dr. R. Jeffrey Karnes, of the department of urology, said in the news release.

The study was slated for presentation May 15 at the annual meeting of the American Urological Association, in Washington, D.C. Research presented at meetings is considered preliminary until it is published in a peer-reviewed journal.

More information

The American Cancer Society has more about prostate cancer.

-- Robert Preidt

SOURCE: Mayo Clinic, news release, May 15, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Obese People at Higher Risk of Infection After Colon Surgery
2. Advanced-stage prostate cancer patients experience 20-year survival rates with surgery
3. Brain Surgery for Mary Tyler Moore to Remove Benign Tumor
4. Synthetic mesh can improve outcome of prolapse surgery
5. Vaginal Mesh Surgery Effective for Bladder Prolapse Repair: Report
6. Weight-Loss Surgery Seems No Riskier for Seniors
7. Stem cell technology used in unique surgery
8. Surgery May Beat Antibiotics for Appendicitis, Study Finds
9. Surgery reduces risk of mortality due to prostate cancer even for low-risk groups
10. Heart Bypass Surgery Rates Drop Dramatically, Study Finds
11. Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients
Post Your Comments:
Related Image:
Surgery Viable for Advanced Prostate Cancer, Study Finds
(Date:11/30/2015)... ... November 30, 2015 , ... An ... directory is specialized and only includes chiropractic clinics in the US. , The ... trustworthy alternative health practitioner when back pain sets in. When people are experiencing ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... Free Press as a Top Workplace , among the ... work for in 2015. ... annually, based on employee surveys rating company leadership, career opportunities, ... based solely on employee feedback. The survey is conducted by ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology: